After 5 years of follow-up, mRNA-based COVID-19 vaccination was independently associated with improved long-term survival in patients with solid tumors who survived COVID-19 hospitalization.

The time of day that intravenous immune checkpoint inhibitor therapy is administered is unlikely to significantly affect OS in NSCLC patients.

Ceralasertib plus durvalumab does not improve overall survival compared to docetaxel in patients with locally advanced/metastatic NSCLC.

A major US accreditation group — the Liaison Committee on Medical Education (LCME) — has removed language from its standards that had urged medical schools to teach about health inequities. The change ...

Investigators sought to determine whether weight-based dosing of pembrolizumab could produce outcomes similar to standard fixed dosing for patients with NSCLC.

Zongertinib has shown “robust activity” in the treatment of advanced, treatment-naïve, HER2-mutant non-small cell lung cancer.

Investigators sought to identify risks of prescription drug promotion by social media influencers and how current evidence can inform future research and effective policy ...

Investigators expanded on previous results from the DEAR study, comparing darolutamide versus enzalutamide and apalutamide ...

In this analysis, researchers evaluated whether beta blocker use is associated with improved survival in patients with solid tumors.

Investigators compared mortality risk among long-term survivors of high-grade serous ovarian cancer versus the general US population to examine how mortality and recurrence trends have changed with ...

In this study, researchers aimed to characterize the relationship between major depressive disorder, use of antidepressants, and risk of recurrence in breast cancer patients.

Investigators assessed differences in efficacy and toxicity of first-line chemotherapy with and without targeted in therapy ...